COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations
Firinu D.;del Giacco S.;
2022-01-01
Abstract
Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.File | Size | Format | |
---|---|---|---|
Allergy - 2022 - Jutel - COVID‐19 vaccination in patients receiving allergen immunotherapy AIT or biologicals EAACI.pdf Solo gestori archivio
Type: versione editoriale
Size 2.2 MB
Format Adobe PDF
|
2.2 MB | Adobe PDF | & nbsp; View / Open Request a copy |
COVID-19 vaccination_ EAACI_recom_final-docx.pdf open access
Type: versione pre-print
Size 1.51 MB
Format Adobe PDF
|
1.51 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.